Skip to main content
Top
Published in: Pituitary 2/2017

01-04-2017

Significance of surgical management for cystic prolactinoma

Authors: Toshihiro Ogiwara, Tetsuyoshi Horiuchi, Alhusain Nagm, Tetsuya Goto, Kazuhiro Hongo

Published in: Pituitary | Issue 2/2017

Login to get access

Abstract

Purpose

It is generally accepted that dopamine agonists (DA) represent the first-line treatment for most patients with prolactinoma, and patients become candidates for surgical intervention when DA is contraindicated. Surgical indication for cystic prolactinoma remains controversial. This study was performed to investigate the significance of surgery for cystic prolactinoma.

Methods

A total of 28 patients that underwent transsphenoidal resection of prolactinoma between February 2004 and May 2016 were reviewed. Five consecutive patients with cystic prolactinoma were included in this study. Our surgical strategy for cystic prolactinoma was categorized as follows: first, when the purpose of surgical resection was normalization of the prolactin level, aggressive resection was performed; second, when volume reduction was essential to relieve the visual symptoms and headache, internal decompression was performed followed by DA therapy. The clinical outcomes were analyzed accordingly.

Results

All cystic prolactinoma were resected via the transsphenoidal approach without any complications, and all symptoms including visual impairment and hypogonadal activity were finally relieved combined with medication.

Conclusions

Surgery for cystic prolactinoma could be a better option. Transsphenoidal surgery is relatively safe to remove the cystic prolactinoma, additionally it can normalize the prolactine level and achieve adequate and rapid decompression of optic chiasm. The risk of transsphenoidal surgery is highly dependent on the skill of the surgeon and treatment decision for cystic prolactinoma needs to be individualized for each patient.
Literature
1.
go back to reference Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A (2006) Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol 65:265–273CrossRef Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A (2006) Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol 65:265–273CrossRef
2.
go back to reference Cohen-Inbar O, Xu Z, Schlesinger D, Vance ML, Sheehan JP (2015) Gamma knife radiosurgery for medically and surgically refractory prolactinomas: long-term results. Pituitary 18:820–830CrossRefPubMed Cohen-Inbar O, Xu Z, Schlesinger D, Vance ML, Sheehan JP (2015) Gamma knife radiosurgery for medically and surgically refractory prolactinomas: long-term results. Pituitary 18:820–830CrossRefPubMed
4.
go back to reference Kreutzer J, Buslei R, Wallaschofski H, Hofmann B, Nimsky C, Fahlbusch R, Buchfelder M (2008) Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol 158:11–18CrossRefPubMed Kreutzer J, Buslei R, Wallaschofski H, Hofmann B, Nimsky C, Fahlbusch R, Buchfelder M (2008) Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol 158:11–18CrossRefPubMed
5.
go back to reference Barrow DL, Mizuno J, Tindall GT (1988) Management of prolactinomas associated with very high serum prolactin levels. J Neurosurg 68:554–558CrossRefPubMed Barrow DL, Mizuno J, Tindall GT (1988) Management of prolactinomas associated with very high serum prolactin levels. J Neurosurg 68:554–558CrossRefPubMed
6.
go back to reference Razzaq AA, Jooma R, Ahmed S (2006) Surgery for prolactinomas. J Pak Med Assoc 56:181–183PubMed Razzaq AA, Jooma R, Ahmed S (2006) Surgery for prolactinomas. J Pak Med Assoc 56:181–183PubMed
7.
go back to reference Bahuleyan B, Menon G, Nair S, Rao BRM, Easwer HV, Krishna K (2009) Non-surgical management of cystic prolactinomas. J Clin Neurosci 16:1421–1424CrossRefPubMed Bahuleyan B, Menon G, Nair S, Rao BRM, Easwer HV, Krishna K (2009) Non-surgical management of cystic prolactinomas. J Clin Neurosci 16:1421–1424CrossRefPubMed
8.
go back to reference Balarini Lima GA, Machado Ede O, Dos Santos Silva CM, Filho PN, Gadelha MR (2008) Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline. Pituitary 11:287–292CrossRefPubMed Balarini Lima GA, Machado Ede O, Dos Santos Silva CM, Filho PN, Gadelha MR (2008) Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline. Pituitary 11:287–292CrossRefPubMed
9.
go back to reference Prague JK, Ward CL, Mustafa OG, Whitelaw BC, King A, Thomas NW, Gilbert J (2014) Delayed presentation of late-onset cerebrospinal fluid rhinorrhea following dopamine agonist therapy for giant prolactinoma. Endocrinol Diabetes Metab Case Rep 11:EDM-14-0020 Prague JK, Ward CL, Mustafa OG, Whitelaw BC, King A, Thomas NW, Gilbert J (2014) Delayed presentation of late-onset cerebrospinal fluid rhinorrhea following dopamine agonist therapy for giant prolactinoma. Endocrinol Diabetes Metab Case Rep 11:EDM-14-0020
10.
go back to reference Smith TR, Hulou MM, Huang KT, Gokoglu A, Cote DJ, Woodmansee WW, Laws ER Jr (2015) Current indications for the surgical treatment of prolactinomas. J Clin Neurosci 22:1785–1791CrossRefPubMed Smith TR, Hulou MM, Huang KT, Gokoglu A, Cote DJ, Woodmansee WW, Laws ER Jr (2015) Current indications for the surgical treatment of prolactinomas. J Clin Neurosci 22:1785–1791CrossRefPubMed
11.
go back to reference Dinc C, Bikmaz K, Iplikcioglu AC, Kosdere S, Latifac I (2008) Cystic giant prolactinoma in childhood. J Clin Neurosci 15:76–79CrossRefPubMed Dinc C, Bikmaz K, Iplikcioglu AC, Kosdere S, Latifac I (2008) Cystic giant prolactinoma in childhood. J Clin Neurosci 15:76–79CrossRefPubMed
12.
go back to reference Gnjidic Z, Kudelic N, Sajko T, Malenica M, Stipic D, Rotim K (2014) Surgical treatment of prolactinomas-our experience. Coll Antropol 38:571–576PubMed Gnjidic Z, Kudelic N, Sajko T, Malenica M, Stipic D, Rotim K (2014) Surgical treatment of prolactinomas-our experience. Coll Antropol 38:571–576PubMed
13.
14.
go back to reference Puataweepong P, Dhanachai M, Hansasuta A, Dangprasert S, Swangsilpa T, Sitathanee C, Jiarpinitnun C, Vitoonpanich P, Yongvithisatid P (2015) The clinical outcome of hypofractionated stereotactic radiotherapy with cyberknife robotic radiosurgery for perioptic pituitary adenoma. Technol Cancer Res Treat. doi:10.1177/1533034615607113 Puataweepong P, Dhanachai M, Hansasuta A, Dangprasert S, Swangsilpa T, Sitathanee C, Jiarpinitnun C, Vitoonpanich P, Yongvithisatid P (2015) The clinical outcome of hypofractionated stereotactic radiotherapy with cyberknife robotic radiosurgery for perioptic pituitary adenoma. Technol Cancer Res Treat. doi:10.​1177/​1533034615607113​
15.
go back to reference Inder WJ, MacFarlane MR (2004) Hyperprolactinaemia associated with a complex cystic pituitary mass: medical versus surgical therapy. Intern Med J 34:573–576CrossRefPubMed Inder WJ, MacFarlane MR (2004) Hyperprolactinaemia associated with a complex cystic pituitary mass: medical versus surgical therapy. Intern Med J 34:573–576CrossRefPubMed
Metadata
Title
Significance of surgical management for cystic prolactinoma
Authors
Toshihiro Ogiwara
Tetsuyoshi Horiuchi
Alhusain Nagm
Tetsuya Goto
Kazuhiro Hongo
Publication date
01-04-2017
Publisher
Springer US
Published in
Pituitary / Issue 2/2017
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-016-0766-6

Other articles of this Issue 2/2017

Pituitary 2/2017 Go to the issue